Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has shared an announcement.
Clarity Pharmaceuticals reported that data from its Phase II Co-PSMA investigator-initiated trial of 64Cu-SAR-bisPSMA in men with biochemical recurrence of prostate cancer were presented at the European Association of Urology Congress 2026 and accepted for publication in European Urology. The study showed that 24-hour 64Cu-SAR-bisPSMA PET/CT outperformed standard-of-care 68Ga-PSMA-11 in lesion detection at low PSA levels, delivering a higher true positive rate, fewer false negatives and driving management changes in 44% of patients.
In the 50-patient head-to-head trial, 64Cu-SAR-bisPSMA identified more lesions overall, particularly in the prostate bed and lymph nodes, and produced a greater proportion of positive scans than 68Ga-PSMA-11. Clarity plans to combine Co-PSMA data with its Phase II COBRA trial and the anticipated pivotal Phase III AMPLIFY results to support a U.S. FDA market authorisation filing for 64Cu-SAR-bisPSMA in patients with recurrent prostate cancer, potentially strengthening its competitive position in prostate cancer imaging and expanding options for clinicians and patients.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$4.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd., listed on the ASX as CU6, is a clinical-stage radiopharmaceutical company focused on developing next-generation diagnostic and therapeutic products for cancer. The company’s pipeline includes copper-based agents such as 64Cu-SAR-bisPSMA, targeting improved detection and management of prostate cancer recurrence in patients eligible for curative salvage therapy.
Average Trading Volume: 2,198,496
Technical Sentiment Signal: Buy
Current Market Cap: A$1.43B
See more data about CU6 stock on TipRanks’ Stock Analysis page.